Hoth Therapeutics’ Wholly Owned Subsidiary Merveille.ai, Advances AI-Driven Discovery for Obesity Treatment

March 27, 2024

https://www.prnewswire.com/news-releases/hoth-therapeutics-wholly-owned-subsidiary-merveilleai-advances-ai-driven-discovery-for-obesity-treatment-302100182.html

Merveille.ai Files Patent for Obesity Treatment, Begins Preparatory Steps for Clinical Trials, Joins Nvidia Developer Program

NEW YORK, March 27, 2024 /PRNewswire/ — Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient focused biopharmaceutical company, is excited to announce a significant breakthrough by its subsidiary, Merveille.ai, in the field of obesity treatment. Utilizing advanced artificial intelligence, Merveille.ai has identified a promising new therapeutic candidate, culminating in a strategic patent filing.

Read more at prnewswire.com

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.